SCHEMBL12289963

SCHEMBL12289963

Nc1n[nH]c2ccc(-c3ccc(NCC4(c5ccccc5)CC4)nn3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 11/20 0.46
▸ CDC7 O00311 12/20 0.44
▸ CDK2 P24941 8/20 0.44
▸ ROCK2 O75116 7/20 0.44
▸ PRKACA P17612 7/20 0.44
▸ GSK3B P49841 7/20 0.44
▸ AURKB Q96GD4 7/20 0.44
▸ JAK3 P52333 6/20 0.44
▸ ROCK1 Q13464 6/20 0.44
▸ MAPK13 O15264 5/20 0.44
▸ DAPK3 O43293 5/20 0.44
▸ PRKCG P05129 5/20 0.44
▸ CDK1 P06493 5/20 0.44
▸ MARK3 P27448 5/20 0.44
▸ GSK3A P49840 5/20 0.44
▸ MAPK12 P53778 5/20 0.44
▸ CSNK2A1 P68400 5/20 0.44
▸ CDK5 Q00535 5/20 0.44
▸ PRKCD Q05655 5/20 0.44
▸ DYRK1A Q13627 5/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12289976 0.96 JAK2 (0.44) JAK2CDC7CDK2ROCK2PRKACA
SCHEMBL12286536 0.90 JAK2 (0.39) JAK2CDC7CDK2ROCK2PRKACA
SCHEMBL12289978 0.86 JAK2 (0.38) JAK2CDC7CDK2ROCK2PRKACA
SCHEMBL14998160 0.86 JAK2 (0.40) JAK2CDC7CDK2ROCK2PRKACA
SCHEMBL12288220 0.86 JAK2 (0.38) JAK2CDC7CDK2ROCK2PRKACA
SCHEMBL12289957 0.85 SLC6A3 (0.39) JAK2CDC7CDK2ROCK2PRKACA
SCHEMBL12289955 0.85 JAK2 (0.44) JAK2CDC7CDK2ROCK2PRKACA
SCHEMBL14998163 0.83 JAK2 (0.39) JAK2CDC7CDK2ROCK2PRKACA
SCHEMBL12287421 0.83 JAK2 (0.39) JAK2CDC7CDK2ROCK2PRKACA
SCHEMBL12287355 0.79 KCNH2 (0.50) JAK2CDC7CDK2ROCK2PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8969346-B2 Amino-pyridazine skeletal muscle modulators CYTOKINETICS, INC. (US) 2015-03-03 — — US claimed
EP-3127541-B1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS INC (US) 2019-07-17 — — EP disclosed
US-20170281621-A1 SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS CYTOKINETICS INC (US) 2017-10-05 — — US disclosed
US-20170281621-A1 SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS CYTOKINETICS INC (US) 2017-10-05 — — US disclosed
US-9604965-B2 Substituted pyridazines as skeletal muscle modulators CYTOKINETICS, INC. (US) 2017-03-28 — — US disclosed
US-9604965-B2 Substituted pyridazines as skeletal muscle modulators CYTOKINETICS, INC. (US) 2017-03-28 — — US disclosed
US-9604965-B2 Substituted pyridazines as skeletal muscle modulators CYTOKINETICS, INC. (US) 2017-03-28 — — US disclosed
EP-3127541-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE Cytokinetics, Inc. (US) 2017-02-08 — — EP disclosed
EP-2563365-B1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS INC (US) 2016-04-20 — — EP disclosed
US-20150322018-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE ASHCRAFT LUKE W (US) 2015-11-12 — — US disclosed
US-20150322018-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE ASHCRAFT LUKE W (US) 2015-11-12 — — US disclosed
US-20150322018-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE ASHCRAFT LUKE W (US) 2015-11-12 — — US disclosed
US-8969346-B2 Amino-pyridazine skeletal muscle modulators CYTOKINETICS, INC. (US) 2015-03-03 — — US disclosed
US-8969346-B2 Amino-pyridazine skeletal muscle modulators CYTOKINETICS, INC. (US) 2015-03-03 — — US disclosed
US-8969346-B2 Amino-pyridazine skeletal muscle modulators CYTOKINETICS, INC. (US) 2015-03-03 — — US disclosed
US-20130143862-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS, INC. 2013-06-06 — — US disclosed
US-20130143862-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS, INC. 2013-06-06 — — US disclosed
US-20130143862-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS, INC. 2013-06-06 — — US disclosed
WO-2011133882-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE CYTOKINETICS, INC. (US) 2011-10-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170281621-A1 SUBSTITUTED PYRIDAZINES AS SKELETAL MUSCLE MODULATORS MUSK, PYGM, GYS1 JAK2 704/4885CDC7 4645/4885CDK2 2681/4885
US-20130143862-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS OF THEIR USE SLC7A1, F12, C5 JAK2 40/4885CDC7 3755/4885CDK2 1642/4885
US-20150322018-A1 CERTAIN AMINO-PYRIDAZINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE SLC7A1, F12, C5 JAK2 41/4885CDC7 3691/4885CDK2 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback